Zoledronic Acid: A Review of its Use in the Treatment of Osteoporosis

Authors: Deeks, Emma D.; Perry, Caroline M.

Source: Drugs & Aging, Volume 25, Number 11, 2008 , pp. 963-986(24)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

Zoledronic acid (Aclasta^®; Reclast^®), a third-generation nitrogen-containing bisphosphonate, is the first once-yearly treatment to have been approved for use in patients with postmenopausal osteoporosis or at high risk of fracture. Intravenous zoledronic acid 5 mg once yearly is effective in reducing the risk of several types of fracture in patients with postmenopausal osteoporosis or recent low-trauma hip fracture. Moreover, improvements in bone mineral density (BMD) and reductions in markers of bone turnover are also generally observed. Zoledronic acid is generally well tolerated. Additional comparative data are required to definitively position zoledronic acid with respect to other agents. In the meantime, intravenous zoledronic acid 5 mg once yearly is a convenient and effective treatment option that may have an advantage over some other agents, for which adherence to treatment regimens is a recognized problem.

Keywords: Adis Drug Evaluations; Osteoporosis; Zoledronic acid

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

Publication date: 2008-01-01